Antitrust/Competition Merger Review

Experience Highlights

• Sony in its $3.6 billion acquisition of games software developer Bungie.
• Abbvie in its $63 billion acquisition of Allergan, the manufacturer of the well-known medication Botox. The Wall Street Journal reported that this was one of the biggest mergers in the healthcare sector in the year it was announced.
• AT&T Inc. in its successful $85.4 billion stock-and-cash acquisition of Time Warner Inc. Arnold & Porter successfully defended this first vertical merger trial and appeal in decades.
• Bristol-Myers Squibb in numerous transactions including its $90 billion acquisition of Celgene.
• Fitbit in its $2.1 billion sale to Google.
• Monsanto Company in obtaining US and EU competition clearances in connection with the company's $66 billion acquisition by Bayer, as well as coordinating antitrust/competition approvals in almost 30 other jurisdictions worldwide.
• General Electric in obtaining antitrust clearance in the US and Europe for the company's €12.35 billion acquisition of Alstom.
• Boston Scientific, as lead worldwide antitrust counsel, in its $4.2 billion acquisition of BTG plc, subject to the UK takeover code, and its related divestiture of microspheres business to Varian Medical Systems.
• Adobe in obtaining clearance regarding the company's $4.75 billion acquisition of Marketo, the leading marketing cloud platform for B2B marketing engagement.
• Pfizer in its $12 billion combination of Upjohn with Mylan and in its $6.7 billion acquisition of Arena Pharmaceuticals.
• Thermo Fisher Scientific in its $21 billion Acquisition of PPD.
• BP, as lead worldwide antitrust counsel, in securing FTC clearance of its $5.6 billion sale of BP's entire business in Alaska, including all of its upstream and midstream businesses in the state, to Hilcorp, the largest private operator in Alaska.